US2014378517A1PendingUtilityA1

Formulations of enzalutamide

Assignee: BEND RESPriority: Sep 11, 2012Filed: Sep 10, 2014Published: Dec 25, 2014

Est. expirySep 11, 2032(~6.1 yrs left)· nominal 20-yr term from priority

Inventors:Douglas Alan Lorenz Sanjay Konagurthu Randy J. Wald Jason A. Everett Sheila Matz Yuuki Takaishi Toshiro Sakai Ryousuke Irie Shinsuke Oba Hiroyasu Toyota Koji Nishimura Atsushi Kanbayashi

A61P 35/00A61P 43/00A61K 9/1652A61P 13/08A61P 15/00A61P 15/14A61P 15/08C07D 233/86A61K 31/4164A61K 9/10A61K 9/2054A61K 31/4166A61K 9/2095A61K 47/38A61K 9/16A61K 47/32A61K 9/2027A61K 9/146A61K 9/1635

PatentIndex Score

Cited by

References

Claims

Abstract

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Claims

exact text as granted — not AI-modified

1 . A pharmaceutical composition comprising a solid dispersion containing enzalutamide and a polymer selected from the group consisting of hydroxypropyl methyl cellulose and hydroxypropyl methylcellulose acetate succinate, wherein the polymer is 0.5 to 7 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the enzalutamide is an amorphous state. 
     
     
         3 . The pharmaceutical composition according to  claim 2 , wherein the polymer is hydroxypropyl methylcellulose acetate succinate. 
     
     
         4 . The pharmaceutical composition according to  claim 3 , which is a tablet. 
     
     
         5 . A method of treating prostate cancer, comprising administering to a patient in need thereof a pharmaceutical composition comprising a solid dispersion containing enzalutamide and a polymer selected from the group consisting of hydroxypropyl methyl cellulose and hydroxypropyl methylcellulose acetate succinate, wherein the polymer is 0.5 to 7 parts by weight, with respect to 1 part by weight of the enzalutamide. 
     
     
         6 . The method of  claim 5 , wherein the enzalutamide is in an amorphous state. 
     
     
         7 . The method of  claim 6 , wherein the polymer is hydroxypropyl methylcellulose acetate succinate. 
     
     
         8 . The method of  claim 7 , wherein the pharmaceutical composition is a tablet.

Join the waitlist — get patent alerts

Track US2014378517A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.